We prospectively evaluated mixed chimerism (MC) in the T cell and myeloid lineages and its correlation to busulphan, single-dose total body irradiation (TBI) and fractionated TBI (fTBI) conditioning in 180 patients with haematological malignancies after allogeneic stem cell transplantation (SCT). In all patients receiving busulphan, the area under curve (AUC) was calculated. The incidence of MC in the T cell lineage was significantly lower in patients receiving fTBI (22%) compared to those given TBI (53%, P ¼ 0.02) or busulphan (47%, Po0.01). The incidence of myeloid MC did not differ between the three groups. The overall probability of acute graft-versus-host disease grades II-IV was significantly higher in patients with complete T cell donor chimerism (49%) compared to patients with T cell MC (23%, Po0.001). The incidence of T cell and myeloid MC after SCT did not differ between low (55%), medium (42%) and high (43%) AUC levels of busulphan during conditioning. Patients receiving fTBI had a significantly higher probability of relapse compared to busulphan-treated patients (44 vs l6%, P ¼ 0.01). In multivariate analysis adjusted for diagnosis, busulphan-treated patients showed both a better survival (P ¼ 0.04) and less probability of relapse (0.03) compared to TBI-treated patients.
total body irradiation; busulphan; leukaemia Allogeneic stem cell transplantation (SCT) is today an accepted treatment for patients with haematological malignancies. 1 The conditioning regimens in SCT play an important role in determining the outcome. The aim of the conditioning therapy is to eradicate malignant cells and to suppress the immune system. High-dose total body irradiation (TBI) remains a major part in most conditioning regimens. Modification of TBI in fractionated schedules has enabled an escalation in total radiation dose. 2 Busulphan combined with cyclophosphamide is frequently used as conditioning therapy, especially in children to avoid side effects of TBI. 3, 4 Some early reports also indicate that busulphan-based conditioning may be an alternative in young children with acute lymphocytic leukaemia. 5 The relation between incidence of mixed chimerism (MC), that is, remaining haematopoietic recipient cells, and conditioning dose intensity has been addressed in several studies. [6] [7] [8] [9] [10] [11] [12] [13] In all studies except one, 13 an increased degree of MC was detected in patients who received less intensive conditioning regimens. The majority of these studies analysed the chimeric status with different techniques in patients with various diseases and only three used PCR of variable number tandem repeats (VNTRs). 7, 11, 12 However, no study has compared single-dose TBI-based conditioning with regimens including busulphan or fractionated TBI (fTBI).
In the present study, we evaluated the incidence and clinical impact of MC after SCT, in T cells and myeloid cells in 180 patients with leukaemia or myelodysplastic syndrome (MDS), receiving TBI, busulphan or fTBI as conditioning therapy in a nonrandomized study. The results of lineage-specific chimerism analysis were also compared with pharmacokinetic analysis of busulphan levels during conditioning.
Materials and methods

Patients
Between September 1996 and June 2001, 180 consecutive patients with leukaemia or MDS who received an allogeneic SCT at Huddinge University Hospital were evaluated with chimerism analysis within T and myeloid cells after SCT. All results from chimerism analysis were kept filed; therefore no tapering or addition of treatment due to chimerism status was performed. A total of 29 patients were excluded from chimerism analysis due to either no samples (13 patients) or no informative primer pair (eight patients). In eight patients, the donor produced the smaller allelic product, hence these patients were excluded in order to obtain the same sensitivity for all analysed patients. 14 A total of 73 patients received SCT from HLA-identical siblings and 107 patients from HLA-A-, B-and -DR-compatible unrelated donors. In all, 99 patients received bone marrow and 81 patients were grafted with peripheral blood stem cells (PBSC). Diagnoses and other patient and donor characteristics for patients receiving either TBI or fTBI or busulphan are given in Table 1 . Details regarding the supportive care have previously been described. 15 The ethics committee at Karolinska Institute, Huddinge Hospital (63/96), approved this study.
Tissue typing
HLA-A and -B class I typing was performed serologically using all commercially available reagents to define new subgroups. Since 1999, the PCR method, using sequencespecific primer pairs, was utilized to define DRB1-5, DQA1, DQB and DPB1 alleles. 16 
Conditioning
Cyclophosphamide (Cy) at 60 mg/kg on two consecutive days (À5 and À4 or À4 and À3) combined with 10 Gy of single-dose TBI (with the lungs shielded to receive no more than 9 Gy) was given to 76 patients. A total of 45 patients received fTBI (3 Gy Â 4) combined with Cy 60 mg/kg on 2 days. A combination of busulphan (4 mg/kg/day Â 4) and Cy at 60 mg/kg was given to 59 patients on two consecutive days. 17 Patients with matched unrelated donors (MUD) received 5 days of (days À5 to À1) treatment with either antithymocyte globulin (IMTIX, Sangstat, Lyon, France) at 2-5 mg/kg/day or with OKT-3 (Janssen-Cilag, Zug, Switzerland) at 5 mg/day before transplantation. 18 Patients with ALL, AML M4 or M5, or patients with a previous history of CNS leukaemia, were given two 12 mg doses of intrathecal methotrexate (MIX) pre-SCT.
Graft-versus-host disease (GVHD) prophylaxis
Most patients received cyclosporine (CsA) combined with a short course of MTX. MTX was administered i.v. at a dose of 15 mg/m 2 on day +1 and 10 mg/m 2 on days 3, 6 and 11 post-SCT. 19 Owing to anticipated liver toxicity, MTX was replaced by prednisolone in nine patients. Two patients received CsA combined with mycophenolate mofetil (MMF) 10-15 mg/kg Â 2, given from day 0 to day 45 after SCT. Cyclosporine A i.v. was started on day -1, dose ranging from 5 to 10 mg/kg/day for patients receiving SCT from MUD and 1 to 3 mg/kg/day for patients with HLAidentical sibling donors. Children received the higher given dose. On the day of SCT, CsA was lowered to 3-7.5 mg/kg/ day for the MUD patients. On day +1, or as soon as the patient could take CsA orally, 12.5 mg/kg/day was given to adults and a higher dose, 12.5-20 mg/kg/day, to children, with a MUD transplant. Siblings received lower doses, 3-6 mg/kg/day. During the first month, blood CsA levels were kept at 200-300 ng/ml for MUD patients and around 100 ng/ml for the siblings. 20 After 6 months, the CsA dose was lowered by 25% every alternate month and was discontinued after 12 months in the MUD group, in the absence of GVHD. In siblings, CsA was discontinued after 6 months.
GVHD
Acute GVHD was diagnosed from clinical symptoms and/ or biopsies from skin, oral mucous membrane, liver and gut. GVHD was graded from 0 to IV, according to previously published criteria. 21 At the first sign of grade I GVHD, prednisolone 2 mg/kg/ day was given to adults and 2-3 mg/kg/day to children, for at least 1 week. 20 Thereafter, the dose was reduced, depending on the response. Some patients with persistent or severe GVHD also received methylprednisolone i.v., ATG or psoralen and ultraviolet light (PUVA). 22 In some patients with recurring GVHD, MTX, 5-10 mg/m 2 , was administered once a week. Chronic GVHD was diagnosed from clinical symptoms and/or biopsies from skin, oral mucous, liver and gut.
Specimens
Peripheral blood (PB) samples were collected from the donor and recipient before transplant and from the recipient on day +14, +21, +28 and monthly thereafter post SCT. DNA from donor and recipient pretransplantation samples was extracted using standard protocols (Qiagen, Hilden, Germany). To evaluate lineage-specific chimerism, selection of CD3-and either CD13-or CD33-or CD45-positive cells (myeloid cells) from PB was done by the use of immunomagnetic beads (Dynal, Oslo, Norway). 23 In order to increase purity, lysis buffer was added to all bead-separated samples. 23 
Chimerism analysis
The methodology of chimerism analysis, within different cell lineages, has been described elsewhere. 23 Mixed chimerism was defined as detection of both recipient-and donor-specific minisatellite alleles in at least one sample after SCT. We have previously demonstrated a sensitivity of 4 Â 10 À4 after cell separation of CD33-positive cells. 23 Pretransplant recipient and donor DNA samples were amplified with five different minisatellite primer pairs to obtain informative locus. To achieve similar PCR amplification efficiency, all patients included in this study produced the smaller allelic product as compared to their corresponding donor. PCR analysis, using the chosen primer pair, was carried out on sequential patient samples. PCR-amplified products were separated, using a ready-touse PAGE system (Pharmacia Biotech, Uppsala, Sweden), by 12.5% nondenaturing polyacrylamide gel electrophoresis (PAGE). PCR-amplified band patterns were analysed in visible light after 90-min automated silver staining procedure (Pharmacia Biotech, Uppsala, Sweden). We used a semiquantitative estimation of MC, where recipient-band intensity and donor-band intensity were compared to dilution experiments in the patient and donor.
Results were estimated and subdivided on a three-degree scale, 1-5, 5-20 and 420%. After digital photodocumentation, PAGE gels were sealed in hybridization bags and stored at +41C, for future reference.
Pharmacokinetic analysis
In all, 55 of 59 patients receiving busulphan during conditioning therapy were evaluated with pharmacokinetic analysis. Blood samples were collected in heparinized tubes before the first dose and at 30, 60, 120, 180, 240, 360, 480 and 600 min after the dose. The trough levels were calculated as the mean of 12 samples from each patient. Samples were collected immediately before each oral dose starting from dose four (where the steady state was reached) to dose 16. Plasma was separated immediately from collected blood samples and stored at À201C. Plasma samples were thawed before analysis for each patient. The appropriate plasma volumes (0.5-1 ml) were transferred to new tubes where sodium iodide (1 ml, 8 m), internal standard (1,5-bis(methanesulphonoxy) pentane; 500 ng in 50 ml acetone) and n-heptane (0.4 ml) were added. Busulphan and the internal standard reacted with sodium iodide for 45 min at 701C under gentle stirring to form 1,4-diiodobutane and 1,5-diiodopentane. The heptane phase was taken for analysis using a gas chromatography with electron capture detection as described previously. 24 The calibration curve using spiked plasma was linear within the range 10-2600 ng/ml. Busulphan concentrations were calculated using Star integration program (Varian, USA).
Busulphan concentration-time data were adjusted to a two-compartment open model using Gauss-Newton (Levenberg-Hartly) criteria. Parameters such as the elimination rate constant, the plasma maximum concentration and the microconstants were estimated. The plasma concentration vs time (area under curve, AUC) from the first dose was calculated from the model-derived parameters and the elimination half-life was calculated from the slope of the terminal phase of elimination.
The pharmacokinetic modelling was performed using WinNonlin version 3.0 (Pharsight, Mountain View, CA, USA). The mean, median and s.d. were calculated using GraphPad, InStat (version 3.0, Graph Pad, San Diego, CA, USA) and all values were expressed as mean7sd.
Statistical analysis
The probabilities of survival, acute GVHD grades II-IV, chronic GVHD, transplant-related mortality (TRM) and relapse were calculated according to the Kaplan-Meier product-limit method. 25 The differences between the conditioning regimens were compared with the log-rank test. 26 Differences concerning T and myeloid cell chimerism in relation to different AUC levels were compared with the w 2 test and corrected with the Yates method. In the multivariate analysis for relapse and survival, adjusted for diagnosis, the Cox proportional regression model was used. All measurements of variation were expressed as medians and ranges. Calculations were performed with Statistica/ W & (StatSoft Inc., Tulsa. OK, USA).
Results
Patients
Median follow-up for patients alive was 28.5 (4-62) months. Acute GVHD grade I developed in 85 patients (47%) and moderate to severe acute GVHD was diagnosed in 59 patients (33%). A total of 20 patients (11%) developed grades III-IV acute GVHD. In this study 67 patients (88%) receiving TBI, 42 (93%) given fTBI and 56 (95%) receving busulphan were at risk of developing chronic GVHD. Altogether, 64 patients developed chronic GVHD during this study. Relapse of the underlying disease occurred in 45 patients. A total of 67 patients died during this study, 43 due to TRM and 24 due to relapse. Engraftment was seen in all patients, no rejection of the transplanted graft occurred.
Chimerism and clinical outcome
T cell MC was detected in 65 of 151 patients (43%) and myeloid MC in 47 of 151 patients (31%). No statistical significant difference in T cell MC incidence between sibling and MUD transplants was found in this study. There was no significant difference in survival between patients with T cell MC (72%) and donor chimerism (60%) (P ¼ 0.12), although there was a tendency for less TRM in patients with T cell MC (15 vs 27%, P ¼ 0.06). The probability of relapse of the underlying disease did not differ between patients with T cell MC and donor chimerism (DC) (32 vs 27%, P ¼ 0.5). The cumulative incidence of acute GVHD grades II-IV was 23% for the T cell MC patients compared to 49% for the DC patients (Po0.001) (Figure 1 ). When separated according to donor type, T cell DC patients receiving SCT from unrelated donors (n ¼ 107) showed a significantly higher cumulative incidence of acute GVHD grades II-IV (47 vs 15%, P ¼ 0.001) compared to MC patients. Among patients with an HLA-identical sibling donor (n ¼ 73), there was no statistically significant difference in cumulative incidence of grades II-IV acute GVHD (47 vs 24%, P ¼ 0.13) between T cell DC and MC patients.
Chimerism and different conditioning regimens
The results of chimerism analysis in the 151 patients tested were compared with the conditioning therapy given before SCT. Patients receiving fTBI showed a significantly lower incidence of T cell MC (22%) compared to patients given TBI (53%, P ¼ 0.02) or busulphan (47%, Po0.01) ( Table 2 ). However, patients receiving fTBI with T cell MC after SCT showed a longer duration of MC compared to patients with MC receiving busulphan or single-dose TBI as conditioning regimen. For patients with fTBI and MC (n ¼ 8), the duration of MC was 104 (24-495) days vs 36 (14-399) days (Po0.01) for busulphan (n ¼ 26) and 31 (14-712) days (P ¼ 0.07) for TBI (n ¼ 31) treated patients. Myeloid MC did not differ in incidence and duration between different conditioning regimens.
Different conditioning regimens and clinical outcome
Survival. Patients receiving busulphan showed a better 3-year survival compared to patients receiving TBI or fTBI (75 vs 55% and 59%, respectively) (P ¼ 0.04) (Figure 2 ). When patients with ALL (n ¼ 52) were excluded, busulphan showed a tendency of increased survival compared to single-dose TBI (74 vs 57%, P ¼ 0.06). For fTBI, survival was 71% (NS) when ALL patients were excluded. In multivariate analysis, adjusted for disease, busulphan showed significantly better survival compared to TBI/fTBI regimens (P ¼ 0.04) ( Table 3) . Patients in CR1 receiving busulphan showed a better 3-year survival compared to patients in 4CR1 (86 vs 54%, P ¼ 0.02). The causes of death in the three conditioning groups are illustrated in Table 4 . TRM. TRM did not show any statistically significant differences between the busulphan, TBI and fTBI regimens (21, 31 and 16%, respectively). There was also a tendency for less TRM among busulphan-treated patients in CR1 compared to patients transplanted in later stages (14 vs 33%, P ¼ 0.08).
Relapse and relapse-free survival. Patients receiving fTBI showed an increased risk of relapse compared to busulphan (44 vs 16%, P ¼ 0.01) (Figure 3 ). When patients with ALL were excluded, five of 16 (31%) patients with fTBI relapsed compared to seven of 54 (13%) patients receiving busulphan (P ¼ 0.09). For patients receiving single-dose TBI, the probability of relapse was 35% with ALL patients included and 28% without (NS). In multivariate analysis, adjusted for disease, busulphan showed less risk of relapse compared to the TBI-based regimens (P ¼ 0.03) ( Table 5) . Relapse-free survival was 67% for busulphan-treated patients compared to 47% for patients receiving TBI/fTBI (P ¼ 0.06). Relapse incidence did not differ between patients with early disease and patients with advanced disease (16 vs 17%).
GVHD. The probability of acute GVHD grades II-IV was 35% for all three conditioning regimens. The probability of chronic GVHD was 67% for patients given single-dose TBI compared to 32% (P ¼ 0.05) for patients receiving fTBI and 41% (Po0.01) for patients given busulphan.
Chimerism and busulphan pharmacokinetics
In 55 of 59 patients receiving busulphan during conditioning therapy, the plasma concentrations and AUCs of busulphan were determined. The AUC for total given doses during conditioning was determined. The mean AUC level for patients with T cell DC after SCT was 86 497 ng h/ml compared to 81 963 ng h/ml for patients with T cell MC. The AUC results were divided into three groups: o80 000, 80-100 000 and 4100 000 ng h/ml. No significant differences were found between the three groups regarding T and myeloid cell MC as shown in Table 6 . In eight patients with AUC below 60 000 ng h/ml, T cell MC was detected in six of eight patients. Relapse incidence did not differ between different AUC levels of busulphan (Table 6) .
Discussion
The clinical impact of MC after allogeneic SCT has been controversial. 27 The influence of different myeloablative conditioning regimens has previously demonstrated an increased incidence of MC after less intensive conditionings. 8, 10, 12 However, a comparison of TBI-based conditioning with regimens including busulphan has not been performed using cell lineage-specific chimerism analysis.
It has previously been suggested that fTBI may be associated with a sparing effect of the recipients' haematopoiesis compared to single-dose TBI.
2 Down et al 28 described that low dose rate and fTBI require higher total doses for equivalent engraftment. Van Os et al 29 reported that split-dose irradiation required about 2 Gy extra for the same level of engraftment as after single-dose TBI. This is supported by the findings in this study since patients given fTBI, receiving 2 Gy more than patients given single-dose TBI, showed less T cell MC. No difference in myeloid MC incidence was found between the conditioning regimens used in the present study. This may be due to a lower sensitivity of the myeloid cell fraction compared to the T cell fraction, as it is well established that the dominating cell populations initially after SCT are granulocytes. Thus, increasing amounts of donor granulocytes may hide the few remaining myeloid cells of recipient origin. Interestingly, patients receiving fTBI with T cell MC detected after SCT showed a more persistent MC compared to patients given single-dose TBI or busulphan. This may support a sparing effect of haematopoietic recipient cells after fTBI. However, only eight patients receiving fTBI showed T cell MC after transplant. These data should therefore be interpreted with caution. Another interesting finding was that despite significantly less T cell MC, fTBI patients showed the same probability of acute GVHD grades II-IV compared to patients receiving busulphan or single-dose TBI. T cell MC has previously been correlated with a lower incidence of moderate to severe acute GVHD after SCT, which is supported by the findings in this study. 30 fTBI has been associated with less tissue toxicity compared to single-dose TBI. 2 The conditioning-related tissue toxicity has been associated with GVHD incidence. 31 Thus, if fTBI may be associated with less tissue damage it may explain why fTBI patients had the same probability of acute GVHD grades II-IV as patients treated with singledose TBI or busulphan, despite less T cell MC. Further studies are needed to evaluate whether this is true or not.
Bolinger et al 7 analysed the impact of busulphan pharmacokinetics during conditioning in children and found a correlation between busulphan at steady state (Css) levels o600 ng/ml and increased level of MC after SCT. This is not supported by the findings in this study, since no significant difference in MC incidence could be found for different AUC levels of busulphan. Also relapse incidence was the same between the different busulphan AUC levels.
In this study, patients treated with busulphan showed a significantly better survival and less probability of relapse compared to patients receiving TBI-based conditioning. This has also been shown in previous studies performed at our unit. 32, 33 However, fTBI-treated patients showed better survival when ALL patients were excluded. This is probably due to the increased risk of relapse in ALL patients compared to patients with CML or AML after SCT. In a randomized trial by the Nordic Bone Marrow Transplantation Group, the incidence of relapse was similar for TBI-and busulphan-treated patients. 17 In the study by Ringde´n et al, 17 busulphan-treated patients with advanced disease showed a significantly lower leukaemiafree survival. In the present study, relapse incidence did not differ between patients given busulphan with early and advanced disease. The reason for this is unknown. However, survival was significantly lower for patients with advanced disease. Therefore, busulphan should probably be avoided in patients with advanced disease if possible. Some studies have also indicated that busulphan may be used in patients with ALL. 5 However, in a large study by Davies et al, 34 Cy/TBI conditioning showed superior survival due to less TRM compared with Bu/Cy conditioning in children with ALL. Therefore, busulphan should probably be avoided also in children with ALL.
Patients receiving fTBI showed a significantly increased risk of relapse compared to busulphan-treated patients and a tendency when patients with ALL were excluded. Patients receiving fTBI had less T cell MC compared with patients given busulphan. However, we and others have previously shown that T cell MC may not be associated with an increased risk of relapse. 30, 35 Instead MC in the leukaemiaspecific cell lineage seems to be correlated with reccurence of the underlying disease. 23 Hagenbeek and Bekkum 36 reported already in 1979 that fTBI was less effective than single-dose TBI in reducing leukaemia cell survival in a rat model. Uckun et al, 37 who suggested that leukaemic progenitor cells are able to repair sublethal damage in a significant portion of ALL patients, supported these findings. In the present study, there was no significant difference in relapse incidence between patients receiving single-dose TBI or fTBI. However, relatively few patients with fTBI were included in this study. Future studies with more patients included are needed to evaluate whether fTBI is combined with an increased risk of relapse or not.
In conclusion, fTBI may be associated with an increased risk of relapse but similar risk of acute GVHD grades II-IV, although T cell MC is significantly less common after this treatment modality compared to busulphan. Busulphan is associated with improved survival, probably due to significantly less risk of relapse, compared to conditioning regimens containing TBI or fTBI. Different AUC levels of busulphan during conditioning do not seem to affect the incidence of MC and relapse after SCT.
